Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation

The oral poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib is approved for the treatment of patients with human epidermal growth factor 2-negative (HER2−) metastatic breast cancer (mBC) and a germline breast cancer susceptibility gene (BRCA) mutation who have been treated with chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartzberg, Lee S., Kiedrowski, Lesli A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024449/
https://www.ncbi.nlm.nih.gov/pubmed/33868464
http://dx.doi.org/10.1177/17588359211006962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024449/
https://www.ncbi.nlm.nih.gov/pubmed/33868464
http://dx.doi.org/10.1177/17588359211006962

Ejemplares similares